Zimmer Biomet (ZBH) signed a definitive agreement to acquire Monogram Technologies (MGRM) for a cash payment of $4.04 per common share, for a total equity value of about $177 million, the companies said Monday.
Shares of Monogram soared 76% as intraday trading volume catapulted to over 13.4 million from a daily average of about 60,000.
Dare Bioscience (DARE) said Monday that interim results from its phase 3 clinical trial showed that its investigational monthly, hormone-free intravaginal contraceptive, Ovaprene, met the company's expectations.
Shares surged 66% as intraday trading volume climbed to more than 63.8 million from a daily average of about 163,000.
Sonnet BioTherapeutics (SONN) shares soared 72% amid heavy trading after the company said it agreed to merge with Rorschach, backed by Atlas Merchant Capital and Paradigm Operations, and will build a reserve of HYPE, the token of the Hyperliquid Layer-1 blockchain.
More than 40.2 million shares of Sonnet traded intraday compared with a daily average of about 2.91 million.
Price: 93.61, Change: -0.19, Percent Change: -0.20
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。